1.Exploring Myelin Dysfunction in Multiple System Atrophy.
Joanna H WONG ; Glenda M HALLIDAY ; Woojin Scott KIM
Experimental Neurobiology 2014;23(4):337-344
Multiple system atrophy (MSA) is a rare, yet fatal neurodegenerative disease that presents clinically with autonomic failure in combination with parkinsonism or cerebellar ataxia. MSA impacts on the autonomic nervous system affecting blood pressure, heart rate and bladder function, and the motor system affecting balance and muscle movement. The cause of MSA is unknown, no definitive risk factors have been identified, and there is no cure or effective treatment. The definitive pathology of MSA is the presence of alpha-synuclein aggregates in the brain and therefore MSA is classified as an alpha-synucleinopathy, together with Parkinson's disease and dementia with Lewy bodies. Although the molecular mechanisms of misfolding, fibrillation and aggregation of alpha-synuclein partly overlap with other alpha-synucleinopathies, the pathological pathway of MSA is unique in that the principal site for alpha-synuclein deposition is in the oligodendrocytes rather than the neurons. The sequence of pathological events of MSA is now recognized as abnormal protein redistributions in oligodendrocytes first, followed by myelin dysfunction and then neurodegeneration. Oligodendrocytes are responsible for the production and maintenance of myelin, the specialized lipid membrane that encases the axons of all neurons in the brain. Myelin is composed of lipids and two prominent proteins, myelin basic protein and proteolipid protein. In vitro studies suggest that aberration in protein distribution and lipid transport may lead to myelin dysfunction in MSA. The purpose of this perspective is to bring together available evidence to explore the potential role of alpha-synuclein, myelin protein dysfunction, lipid dyshomeostasis and ABCA8 in MSA pathogenesis.
alpha-Synuclein
;
Autonomic Nervous System
;
Axons
;
Blood Pressure
;
Brain
;
Cerebellar Ataxia
;
Dementia
;
Heart Rate
;
Lewy Bodies
;
Membranes
;
Multiple System Atrophy*
;
Myelin Proteins
;
Myelin Sheath*
;
Neurodegenerative Diseases
;
Neurons
;
Oligodendroglia
;
Parkinson Disease
;
Parkinsonian Disorders
;
Pathology
;
Risk Factors
;
Urinary Bladder
2.Brain Banking for Research into Neurodegenerative Disorders and Ageing.
Claire E SHEPHERD ; Holly ALVENDIA ; Glenda M HALLIDAY
Neuroscience Bulletin 2019;35(2):283-288
Advances in cellular and molecular biology underpin most current therapeutic advances in medicine. Such advances for neurological and neurodegenerative diseases are hindered by the lack of similar specimens. It is becoming increasingly evident that greater access to human brain tissue is necessary to understand both the cellular biology of these diseases and their variation. Research in these areas is vital to the development of viable therapeutic options for these currently untreatable diseases. The development and coordination of human brain specimen collection through brain banks is evolving. This perspective article from the Sydney Brain Bank reviews data concerning the best ways to collect and store material for different research purposes.
Aging
;
pathology
;
physiology
;
Biomedical Research
;
methods
;
Brain
;
pathology
;
physiopathology
;
Humans
;
Neurodegenerative Diseases
;
pathology
;
physiopathology
;
therapy
;
Tissue Banks
;
Tissue Preservation